TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 131 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2015. The put-call ratio across all filers is 2.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $72,000 | -40.5% | 25,990 | -23.6% | 0.00% | – |
| Q2 2018 | $121,000 | +47.6% | 34,011 | +27.9% | 0.00% | – |
| Q1 2018 | $82,000 | -97.6% | 26,601 | -95.2% | 0.00% | -100.0% |
| Q4 2017 | $3,475,000 | -14.3% | 551,637 | -6.9% | 0.01% | -16.7% |
| Q3 2017 | $4,055,000 | +336.0% | 592,799 | +354.9% | 0.01% | +200.0% |
| Q2 2017 | $930,000 | -19.9% | 130,320 | +3.2% | 0.00% | 0.0% |
| Q1 2017 | $1,161,000 | +75.6% | 126,315 | -23.0% | 0.00% | +100.0% |
| Q4 2016 | $661,000 | -10.3% | 164,062 | -14.8% | 0.00% | 0.0% |
| Q3 2016 | $737,000 | -14.4% | 192,543 | +124.2% | 0.00% | 0.0% |
| Q4 2015 | $861,000 | +212.0% | 85,879 | +132.3% | 0.00% | – |
| Q3 2015 | $276,000 | -67.2% | 36,965 | +108.1% | 0.00% | -100.0% |
| Q2 2015 | $842,000 | +26.4% | 17,765 | -2.4% | 0.00% | +100.0% |
| Q1 2015 | $666,000 | +420.3% | 18,200 | +0.2% | 0.00% | – |
| Q2 2013 | $128,000 | – | 18,170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 354,300 | $7,068,000 | 2.77% |
| Opaleye Management Inc. | 169,700 | $3,385,515,000 | 2.64% |
| Broadfin Capital, LLC | 959,247 | $19,137,000 | 2.01% |
| Novo Holdings A/S | 900,000 | $17,955,000 | 1.75% |
| Eventide Asset Management | 300,900 | $6,003,000 | 0.84% |
| EAM Investors, LLC | 152,595 | $3,044,000 | 0.62% |
| COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT | 497,858 | $9,932,000 | 0.51% |
| Granite Point Capital Management, L.P. | 40,000 | $798,000 | 0.40% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,191 | $8,981,000 | 0.33% |
| TFS CAPITAL LLC | 133,070 | $2,655,000 | 0.23% |